| 
			
			 A nationally representative online survey of 16,280 U.S. adults 
			found that many ascribe health benefits to marijuana that haven't 
			been proven, researchers report in Annals of Internal Medicine. 
 "The American public has a much more favorable point of view than is 
			warranted by the evidence," said the study's lead author, Dr. 
			Salomeh Keyhani of the University of California, San Francisco. 
			"Perhaps most concerning is that they think that it prevents health 
			problems."
 
 While studies have shown that cannabis can help quiet seizures in 
			children with hard to treat epilepsy, quell the nausea and vomiting 
			that can accompany chemotherapy and sooth nerve pain, there's no 
			evidence that it can help with the vast majority of other medical 
			conditions, Keyhani said. And yet, people think of it as a cure all, 
			she added.
 
 "Google marijuana benefits and the top hit is a Business Insider 
			story titled '23 Health Benefits of Marijuana,'" Keyhani said.
 
			
			 
			The new survey looked at public perceptions of the benefits and 
			risks of cannabis. Keyhani and her colleagues found that more than 
			one third (36.9 percent) of respondents thought edible marijuana 
			could prevent health problems, and more than a quarter (29.2 
			percent) believed smoking or vaping marijuana was protective.
 While 76 percent believed marijuana could be addictive, 22.4 percent 
			thought it had no addictive potential. Scientists have found that 
			nine percent of people become addicted to cannabis.
 
 Heartening news - that 92.1 percent thought marijuana was unsafe 
			during pregnancy - was undercut by the fact that 7.3 percent thought 
			it was somewhat or completely safe. "That 7 percent is a lot of 
			people who think that it's OK during pregnancy," Keyhani said.
 
 Also worrisome is the fact that 27.6 percent thought driving while 
			under the influence of marijuana was safer than driving while drunk.
 
 Keyhani suspects that a big part of the problem is that there is 
			little, if any, regulation of cannabis advertising. "It's a 
			multibillion dollar industry," she said. "That's big business."
 
			
            [to top of second column] | 
 
			Another part of the problem is that Americans seem to conflate 
			legality with safety, said Dr. Ajay Wasan, a professor of 
			anesthesiology and psychiatry at the University of Pittsburgh School 
			of Medicine and vice chair for pain medicine at the University of 
			Pittsburgh Medical Center.
 "People perceive it as more like a dietary supplement than as a 
			Schedule I drug with addiction potential," said Wasan, who is 
			unaffiliated with the new study.
 
			Classification of marijuana as a Schedule I drug, which puts it in 
			the same category as heroin, LSD and ecstasy, has gotten in the way 
			of a lot of research, said Dr. Timothy Fong, a professor of 
			addiction psychiatry at the University of California, Los Angeles, 
			and a faculty member of the UCLA Cannabis Research Initiative.
 When a substance is Schedule I, scientists need to jump through a 
			lot of regulatory hoops to do research, Fong said. "We want to do 
			more studies, but we can't do a darn thing if the federal government 
			handcuffs us," he added. "This is the kind of study (Keyhani's) that 
			I think elevates the discussion. And it shows we have a long way to 
			go."
 
 Fong suspects that with little actual data on cannabis, the public 
			gets their information from "pop culture, television shows, 
			celebrities, social media and cannabis conventions."
 
 One big reason people think cannabis is safe is there aren't 
			overdose deaths, said Fong. But that doesn't mean there aren't any 
			deaths. "People get intoxicated and they fall off roofs or they get 
			into automobile accidents," Fong said. "Sometimes they show up in 
			the hospital with a psychotic condition."
 
			
			 
			Without research, laws are driven by politics, Fong said, adding "I 
			like science based legislation."
 SOURCE: http://bit.ly/2wYH0qu Annals of Internal Medicine, online 
			July 23, 2018.
 
			[© 2018 Thomson Reuters. All rights 
				reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |